Edge Therapeutics Inc. (NASDAQ:EDGE) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Edge Therapeutics, Inc. is a biotechnology company which discovers, develops and commercializes hospital-based therapies for acute life-threatening neurological conditions. Its lead product candidate which are in preclinical trial EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage, EG-1964, to prevent recurrent bleeding after treatment for cSDH and EG-1963, to prevent rebleeding following surgeries outside the brain. Edge Therapeutics, Inc. is headquartered in Berkeley Heights, New Jersey. “

Edge Therapeutics (NASDAQ:EDGE) opened at 12.37 on Tuesday. The company’s market capitalization is $357.68 million. Edge Therapeutics has a one year low of $6.23 and a one year high of $14.84. The firm’s 50-day moving average price is $10.85 and its 200 day moving average price is $9.89.

In other Edge Therapeutics news, insider Brian A. Leuthner sold 7,500 shares of the firm’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $10.25, for a total value of $76,875.00. Following the completion of the sale, the insider now directly owns 260,479 shares in the company, valued at $2,669,909.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 44.29% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of EDGE. BlackRock Advisors LLC raised its stake in shares of Edge Therapeutics by 76.4% in the third quarter. BlackRock Advisors LLC now owns 9,752 shares of the company’s stock valued at $102,000 after buying an additional 4,223 shares during the period. TLP Group LLC bought a new stake in shares of Edge Therapeutics during the third quarter valued at approximately $102,000. Nationwide Fund Advisors raised its stake in shares of Edge Therapeutics by 71.7% in the second quarter. Nationwide Fund Advisors now owns 10,247 shares of the company’s stock valued at $104,000 after buying an additional 4,280 shares during the period. Mark Sheptoff Financial Planning LLC raised its stake in shares of Edge Therapeutics by 980.0% in the second quarter. Mark Sheptoff Financial Planning LLC now owns 10,800 shares of the company’s stock valued at $109,000 after buying an additional 9,800 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Edge Therapeutics during the third quarter valued at approximately $130,000. Institutional investors and hedge funds own 48.51% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Edge Therapeutics Inc. (EDGE) Rating Increased to Hold at Zacks Investment Research” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/24/edge-therapeutics-inc-edge-rating-increased-to-hold-at-zacks-investment-research.html.

About Edge Therapeutics

Edge Therapeutics, Inc is a clinical-stage biotechnology company. The Company discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions. The Company’s product candidates include EG-1962 and EG-1964.

5 Day Chart for NASDAQ:EDGE

Receive News & Stock Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related stocks with our FREE daily email newsletter.